CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

BMC Cancer · 2015 · PMC4609094 · PMID 26475344

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

did not reach statistical significancep = 0.094so close (0.05 < p ≤ 0.1)

Concomitant cisplatin treatment was also associated with a better LRC (59 vs 18 months p = 0.022) and better PFS (49 vs 14 months p = 0.024) in these patients, but OS did not reach statistical significance (60 vs 27 months p = 0.094).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.